Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy

References

• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prev Med 2013; 44:373-81; PMID:23498103; http://dx.doi.org/10.1016/j.amepre.2012.11.035
   PubMed Web of Science ®Google Scholar
• Weycker D., Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥ 50 years. Vaccine 2012; 30:5437-44; PMID:22728289; http://dx.doi.org/10.1016/j.vaccine.2012.05.076
   PubMed Web of Science ®Google Scholar
• Smith KJ, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine 2013; 31:3950-6; PMID:23806240; http://dx.doi.org/10.1016/j.vaccine.2013.06.037
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831
   PubMed Web of Science ®Google Scholar
• Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine 2013; 31:6011-21; PMID:24148572; http://dx.doi.org/10.1016/j.vaccine.2013.10.024
   PubMed Web of Science ®Google Scholar
• Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in italy. Hum Vaccin Immunother 2013; 9:699-706; PMID:23295824; http://dx.doi.org/10.4161/hv.23268
   PubMed Web of Science ®Google Scholar
• Liguori G, Parlato A, Zamparelli AS, Belfiore P, Gallé F, Di Onofrio V, Riganti C, Zamparelli B. Società Italiana di Health Horizon Scanning (SIHHS). Adult immunization with 13-valent pneumococcal vaccine in campania region, south italy: an economic evaluation. Hum Vaccin Immunother 2014; 10:492-7; PMID:24185467; http://dx.doi.org/10.4161/hv.26888
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in england using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345:e6879; PMID:23103369; http://dx.doi.org/10.1136/bmj.e6879
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥ 65 years in the netherlands. Clin Ther 2010; 32:1517-32; PMID:20728764; http://dx.doi.org/10.1016/j.clinthera.2010.06.016
   PubMed Web of Science ®Google Scholar
• Pradas R, Gil de Miguel A, Álvaro A, Gil-Prieto R, Lorente R, Méndez C, Guijarro P, Antoñanzas F. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis 2013; 13:175; PMID:23578307; http://dx.doi.org/10.1186/1471-2334-13-175
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Prevenar 13. Available at: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/farmaco?farmaco=039550
   Google Scholar
• European Medicines Agency (EMA). Prevenar 13. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001104/human_med_001220.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother 2013: 9(3):699-706; PMID:23295824; http://dx.doi.org/10.4161/hv.23268
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, for the AGEDD Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8(4):e60273; PMID:23565216; http://dx.doi.org/10.1371/journal.pone.0060273
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Cost effectiveness and strategic planning (WHO-CHOICE). Cost-effectiveness thresholds. Available at: http://www.who.int/choice/costs/CER_thresholds/en/
   Google Scholar
• Dirmesropian S, Wood JG, MacIntyre CR, Newall AT. A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother 2015; 11(4):818-25; PMID:25933180; http://dx.doi.org/10.1080/21645515.2015.1011954
   PubMed Web of Science ®Google Scholar
• Demo.istat. Demografia in cifre. Istituto Nazionale di Statistica. Popolazione residente al 1 Gennaio 2015 per età, sesso e stato civile. Available at: http://demo.istat.it
   Google Scholar
• Viegi G, Pistelli R, Cazzola M, Falcone F, Cerveri I, Rossi A, Ugo Di Maria G. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med 2006; 100:46-55; PMID:16046113; http://dx.doi.org/10.1016/j.rmed.2005.04.013
   PubMed Web of Science ®Google Scholar
• Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, Lim WS. Serotype prevalence in adults hospitalized with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012; 67:540-5; PMID:22374921; http://dx.doi.org/10.1136/thoraxjnl-2011-201092
   PubMed Web of Science ®Google Scholar
• Merito M, Giorgi Rossi P, Mantovani J, Curtale F, Borgia P, Guasticchi G. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. Vaccine 2007; 25:458-65; PMID:17049685; http://dx.doi.org/10.1016/j.vaccine.2006.08.005
   PubMed Web of Science ®Google Scholar
• Schito GC, Fadda G, Nicoletti G, Debbia EA. Streptococcus pneumoniae isolati da malattie invasive e infezioni respiratorie in soggetti adulti e anziani (> 50 anni) ospedalizzati in Italia: studio clinico-microbiologico retrospettivo. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica 2011; 15:75-98
   Google Scholar
• Agenzia Nazionale per i Servizi Sanitari Regionali. (Age.na.s.). Ricoveri ospedalieri, i sistemi tariffari regionali vigenti nell'anno 2009. Available at: www.agenas.it/index.htm
   Google Scholar
• Potena A, Simoni M, Cellini M, Cartabellotta A, Ballerin L, Piattella M, Putinati S. Management of community-acquired pneumonia by trained family general practitioners. Int J Tuberc Lung Dis 2008; 12:19-25; PMID:18173872
   PubMed Web of Science ®Google Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960-8; PMID:12809452; http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00007
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831
   PubMed Web of Science ®Google Scholar